SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed on June 4, 2015, reporting events occurring on June 3, 2015. The registrant is ChromaDex Corporation, a Delaware corporation, reporting on behalf of its wholly owned subsidiary, ChromaDex, Inc. The filing addresses the entry into a material definitive agreement regarding intellectual property licensing.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on the terms of a new licensing agreement rather than financial performance metrics.
Material Changes
On June 3, 2015, ChromaDex entered into a Restated and Amended Exclusive License Agreement with The University of Mississippi (UM). Key changes include:
- Expanded Rights: UM granted ChromaDex an exclusive, worldwide, royalty-bearing license to an additional patent right relating to Pterostilbene, an antioxidant found in berries and nuts. This specific patent right was not covered under the original 2010 agreement or the 2011 amendment.
- Financial Obligations: ChromaDex agreed to make certain cash payments to UM in consideration for the additional license. The company will also continue paying earned royalties on net sales of licensed products and is subject to annual minimum royalty payments.
- Term: The agreement terminates on the earliest of the expiration of the last patent right, a default by ChromaDex, or upon prior written notice by ChromaDex.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or a discussion of risks beyond the standard terms of the agreement. The full text of the agreement, including specific payment amounts, is not included in this filing; it will be attached to the Quarterly Report on Form 10-Q for the quarter ended July 4, 2015. The registrant intends to seek confidential treatment for certain terms of the agreement.
Investor Verification Checklist
- Verify the specific cash payment amounts and annual minimum royalty obligations in the upcoming Form 10-Q for the quarter ended July 4, 2015.
- Confirm the scope of the "additional patent right" for Pterostilbene to assess the competitive advantage gained.
- Review the press release (Exhibit 99.1) for any additional context on the strategic importance of this license.
- Monitor future filings for any disclosures regarding confidential terms that may impact future cash flows.